ClinicalTrials.gg
RecruitingNCT07052877GUAVAUpdated Aug 13, 2026

The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab

An observational study in Glioblastoma and Glioblastoma Multiforme (GBM), sponsored by Royal North Shore Hospital. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Royal North Shore Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 68 studies in Glioblastoma with a site in Australia — 19 open to participants now, 29 under way, 4 of them phase 3. Glioblastoma · Australia.

Started
2025
with 6 others
Observational
3 of 68
3 open now
Primary completion
2027-07
later than 11 of 28 live
Registered
63rd of 68
by date

Among the 68 studies in Glioblastoma with a site in Australia, this one is one of 7 that started in 2025, is one of 3 observational ones, reaches primary completion later than 11 of the 28 other live ones, and was the 63rd registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

19 of the 68 studies in Glioblastoma with a site in Australia are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Glioblastoma with a site in Australia, or all of them as a file.
02

Study summary

This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.

03

Conditions studied

  • Glioblastoma
  • Glioblastoma Multiforme (GBM)

Keywords

  • glioblastoma
  • anti-VEGF
  • PSMA
  • bevacizumab
  • VEGF
  • glioma
  • astrocytoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Glioblastoma patients receiving Bevacizumab as part of standard of care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 18 year of age
  • 0-2
  • Able to provide for the study
  • Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
  • Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
  • For bevacizumab treatment as per treating physician
  • Able to comply with trial requirements

Exclusion criteria

Exclusion Criteria:

  • No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
  • Any to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
  • Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
  • Does not fulfill PBS requirements for bevacizumab
  • Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with glioblastoma receiving Bevacizumab as part of their standard of care

    Diagnostic Test: PSMA PET/CT scan

Interventions

  • Diagnostic testPSMA PET/CT scan

    PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.

06

What researchers measure

Primary outcomes

  1. Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration.

    Time frame: Prior to first administration of bevacizumab to 6 weeks after.

Other outcomes

  1. Changes in PSMA PET SUVmax before and after bevacizumab administration.

    Time frame: Prior to first administration of bevacizumab to 6 weeks after.

  2. Changes in PSMA PET SUVmean before and after bevacizumab administration.

    Time frame: Prior to first administration of bevacizumab to 6 weeks after.

  3. Changes in PSMA PET SUVpeak before and after bevacizumab administration.

    Time frame: Prior to first administration of bevacizumab to 6 weeks after.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.

Of 85 non-industry observational studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 96. This study's planned 19 months is below that.

Counting every sponsor, half of 100 studies reached it within 52 months; a quarter within 33 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 7, 2025
StartActual
Dec 11, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07052877
Lead sponsor
Royal North Shore Hospital
Responsible party
Alexander Yuile (Principal Investigator, Royal North Shore Hospital) — Principal investigator
First posted
Jul 7, 2025
Start date
Dec 11, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 13, 2026

Study contacts

Alexander Yuile
Contact
Alexander.Yuile@health.nsw.gov.au
+61 2 94631171

Oversight

FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion